InnoCare's Combination Therapy Gets Breakthrough Therapy Designation for Marginal Zone Lymphoma
InnoCare Pharma announced that its combination of orelabrutinib and mesutoclax (ICP-248) received Breakthrough Therapy Designation from China's Center for Drug Evaluation for treating patients with marginal zone lymphoma who have received at least one prior therapy. Orelabrutinib is a highly selective BTK inhibitor developed by the company, while mesutoclax is a novel oral BCL2 inhibitor, both designed to improve efficacy and safety.
InnoCare Pharma announced that its combination regimen of orelabrutinib and mesutoclax (ICP-248) has been granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration, for the treatment of patients with marginal zone lymphoma (MZL) who have received at least one prior therapy.
Orelabrutinib is a highly selective, novel BTK inhibitor independently developed by InnoCare, designed to avoid adverse reactions caused by off-target effects and to significantly improve efficacy and safety. Mesutoclax is a novel oral, highly selective BCL2 inhibitor independently developed by the company, which restores apoptosis of tumor cells by selectively inhibiting the BCL2 protein, thereby suppressing tumor growth and spread.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 50/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.